Vimarsana
Biggest News Aggregation in the World

Page 7 - Drug Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Application Today - Breaking & Trending Today

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results - Vistagen Therapeutics (NASDAQ:VTGN) - Vimarsana News

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results - Vistagen Therapeutics (NASDAQ:VTGN)

Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Vimarsana News

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Preventio...

Yet Another Update On Medical Abortion Litigation: PhRMA's Amicus Brief In Support Of Petition For U.S. Supreme Court Review Of The Fifth Circuit Decision - Life Sciences, Biotechnology & Nanotechnology - Vimarsana News

Yet Another Update On Medical Abortion Litigation: PhRMA's Amicus Brief In Support Of Petition For U.S. Supreme Court Review Of The Fifth Circuit Decision - Life Sciences, Biotechnology & Nanotechnology

We have posted a few times (here, here, and here) about the Alliance for Hippocratic Medicine v. FDA/Alliance for Hippocratic Medicine v. Danco Labs., LLC litigation...

Source: mondaq.com
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) - Vimarsana News

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission to...

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device - Vimarsana News

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Oct. 09, 2023 -- Supernus Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ...